TOVXHealthcare · BiotechnologyThe 1 Wall Street analysts covering Theriva Biologics, Inc. hold a median 12-month price target of $4 — +2683.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 13 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Theriva Biologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TOVX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2683.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Mar 2026 | Maxim Group | Upgrade | Buy | — |
| 8 May 2025 | Maxim Group | Downgrade | Hold | — |
| 13 Nov 2024 | Maxim Group | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TOVX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Nov 2026, Theriva Biologics, Inc. returned −48.7% against +13.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 8% of US stocks
Cheaper than 81% of US stocks
Cheaper than 62% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 13% of US stocks
Higher than 18% of US stocks
Higher than 99% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Theriva Biologics, Inc. has a market value of $6.6M and an enterprise value of −$441K.
Revenue in the twelve months to 30 June 2026: $300K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$11.6M, a −3872.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$12.8M.
Trailing P/E: 0.2×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 4184.10%, paying out 0% of earnings.
Theriva Biologics, Inc. employs 15 people — $20K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Theriva Biologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Theriva Biologics reported its third-quarter 2026 operational highlights and financial results. The company said VIRAGE2 enrollment is expected to be complete in Q4 2026, with initial data expected by Q3 2027.
Why it matters — TOVX watchers may note the expected timeline for completing VIRAGE2 enrollment and reporting initial data.
Theriva Biologics sold its antibiotic-degrading enzyme portfolio, including SYN-004, SYN-007 and SYN-006, to Biossil Labs. Theriva received $350,000 at closing and may receive up to $91 million in regulatory and sales milestones, plus low single-digit royalties on net product sales; Biossil assumes future development and commercialization costs and responsibilities.
Why it matters — The transaction transfers future development and commercialization responsibilities for the portfolio to Biossil while providing Theriva upfront payment and potential milestone and royalty revenue.
Theriva Biologics announced that detailed results from the VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer patients were published in Nature Medicine after rigorous peer review. The company noted the data support an immune-mediated mechanism of action and that repeated VCN-01 dosing is being evaluated in the VIRAGE2 Phase 2a trial.
Why it matters — Publication in the premier journal Nature Medicine validates the VIRAGE study and supports continued evaluation of VCN-01, a key pipeline candidate, in metastatic pancreatic cancer.
Theriva Biologics announced that the first patient has been dosed in the VIRAGE2 Phase 2a clinical trial, which evaluates more frequent dosing of VCN-01 (zabilugene almadenorepvec) in first-line patients with metastatic pancreatic ductal adenocarcinoma. The exploratory study is designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 trial.
Why it matters — A TOVX watcher would care because this marks clinical progress for VCN-01 and generates data that could inform the design of a future pivotal Phase 3 trial in metastatic pancreatic cancer.
The 1 Wall Street analysts covering Theriva Biologics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Theriva Biologics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Theriva Biologics, Inc. 52 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Theriva Biologics, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +2683.6% from the last close, and Ticker Nerd's factor model ranks Theriva Biologics, Inc. 52 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Theriva Biologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TOVX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
Theriva Biologics, Inc. returned -48.7% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Theriva Biologics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer and related diseases with significant unmet medical needs.
The most recent item we track (GlobeNewsWire, 12 Nov 2026): "Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results". Theriva Biologics reported its third-quarter 2026 operational highlights and financial results. The company said VIRAGE2 enrollment is expected to be complete in Q4 2026, with initial data expected by Q3 2027.
Theriva Biologics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer and related diseases with significant unmet medical needs. The company’s current pipeline centers on oncolytic adenovirus technology, including VCN-01, an investigational program designed to selectively attack tumor cells and support the delivery of co-administered cancer therapies. Theriva Biologics is also advancing microbiome-related candidates such as SYN-004 and SYN-020, which are intended to help preserve the gut microbiome during antibiotic treatment and address complications linked to microbiome disruption. Its programs span oncology, infectious disease prevention, and gastrointestinal health, reflecting a diversified approach to therapeutic development. Based in Rockville, Maryland, Theriva Biologics operates as a research-driven developer of novel treatment platforms for areas where current options remain limited.
CEO Mr. Steven A. Shallcross CPA · 15 employees · United States · https://therivabio.com
